SARS News and Research

RSS

SARS-CoV-2 spike engagement of ACE2 shown to prime S2′ site cleavage and fusion initiation

In a new study, researchers used a cell-cell fusion assay to extract potentially cleaved spike protein products from syncytia in order to explore the functional and biochemical characteristics of spike (S) protein when it engages its receptor ACE2 in living cells.

10 Jan 2022

Association of vaccination status with Long COVID symptoms

Scientists examined whether vaccination was associated with reporting long-term symptoms post-SARS-CoV-2 infection.

10 Jan 2022

Researchers plan to review the effect of SARS-CoV-2 on male reproductive health

In a protocol published in BMJ Open, researchers from the Chengdu University of Traditional Chinese Medicine plan to review current studies in this area.

10 Jan 2022

Strategy for capturing SARS-CoV-2 through functionalized cellulose materials

Researchers from Northeastern University have developed a new, more cost-effective method for immobilizing SARS-CoV-2.

10 Jan 2022

SARS-CoV-2 Delta sublineage AY.4.2 shows no increase in cell entry or antibody evasion

Researchers from Germany, in their recent study published in the journal Cellular & Molecular Immunology, have evaluated the mutations in the S protein of one such SARS-CoV-2 strain, a Delta sublineage AY.4.2, which is currently expanding in the UK, and have found that it neither contains any potential for increased cell entry nor antibody escape.

10 Jan 2022

New lab-on-a-chip platform for detecting SARS-CoV-2 in resource-limited settings

A recent study shows how a novel and integrated lab-on-a-chip platform can represent a rapid, affordable, and exact molecular diagnostic tool for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The paper is currently available for free on the medRxiv* preprint server while it undergoes peer review.

9 Jan 2022

NYBC discovers novel small-molecule pancoronavirus fusion inhibitors

New York Blood Center has published a study that reports the discovery of highly potent small molecules with the ability to inhibit COVID-19 in infected individuals.

9 Jan 2022

History of SARS-CoV-2 infection affects longitudinal responses to BNT162b2 vaccine

In a recently published article in the journal Cell Reports, scientists have demonstrated that individuals with or without a history of coronavirus disease 2019 (COVID-19) exhibit differential humoral and cellular immune responses 14 days after receiving mRNA-based COVID-19 vaccine developed by Pfizer/BioNTech. However, at a later time point, the responses become comparable between the two groups.

9 Jan 2022

Influenza vaccination does not affect risk of SARS-CoV-2 infection or COVID-19

A new study published in The Journal of Infectious Diseases examined if influenza vaccination altered the risk of SARS-CoV-2 infection and clinical outcomes of COVID-19. The study included health care workers (HCWs) from Denmark who were offered influenza vaccination.

9 Jan 2022

Engineered small extracellular vesicles for the neutralization of SARS-CoV-2

Characterizing these engineered sEVs, the researchers demonstrated that the soluble angiotensin-converting enzyme 2 (sACE-2) loaded sEV successfully binds and thus inhibits the entry of wild-type SARS-CoV-2 as well as its variants, protecting against SARS-CoV-2 infection. They also demonstrated the therapeutic efficacy of these engineered sEVs in vivo.

9 Jan 2022

Bolstering current therapeutic antibody treatments to help fight Omicron infections

Researchers test the neutralizing action of a panel of eight therapeutic monoclonal antibodies against the SARS-CoV-2 Omicron (B.1.1.529) variant.

9 Jan 2022

SARS-CoV-2 Omicron variant uses endosomal entry pathway and grows in upper respiratory tract cells

Researchers demonstrate that the SARS-CoV-2 Omicron variant grows rapidly in human primary nasal epithelial cultures.

9 Jan 2022

Emerging SARS-CoV-2 B.1.619 and B.1.620 variants in South Korea

Researchers investigate the spread and transmission ability of SARS-CoV-2 lineages B.1.619 and B.1.620 in South Korea.

9 Jan 2022

SARS‑CoV‑2 Omicron variant escapes monoclonal antibodies

Researchers determine the neutralizing activity of four mAbs against ten strains of SARS-CoV-2.

9 Jan 2022

Lab engineered human A549 lung cell model conducive for investigating SARS-CoV-2 antivirals

Researchers developed a human A549 lung epithelial cell-based model to probe SARS-CoV-2 replication.

9 Jan 2022

SARS-CoV-2 Omicron a product of offensive evolution with compromised antigenicity

Researchers investigate the relationship between the SARS-CoV-2 Omicron variant and immune system based on self/nonself short constituent sequences.

9 Jan 2022

Slight pH adjustment may turn a metabolic inhibiting drug into promising COVID-19 treatment

Mechanical engineering and materials science professor David Needham has shown that a slight increase in solution pH might be all it takes to turn a metabolic inhibiting drug, traditionally used to treat gut parasites, into a promising prophylactic/preventative nasal spray and early treatment throat spray for COVID-19.

7 Jan 2022

SARS News and Research

SARS-CoV-2 spike engagement of ACE2 shown to prime S2′ site cleavage and fusion initiation

Association of vaccination status with Long COVID symptoms

Researchers plan to review the effect of SARS-CoV-2 on male reproductive health

Strategy for capturing SARS-CoV-2 through functionalized cellulose materials

SARS-CoV-2 Delta sublineage AY.4.2 shows no increase in cell entry or antibody evasion

New lab-on-a-chip platform for detecting SARS-CoV-2 in resource-limited settings

NYBC discovers novel small-molecule pancoronavirus fusion inhibitors

History of SARS-CoV-2 infection affects longitudinal responses to BNT162b2 vaccine

Influenza vaccination does not affect risk of SARS-CoV-2 infection or COVID-19

Engineered small extracellular vesicles for the neutralization of SARS-CoV-2

Bolstering current therapeutic antibody treatments to help fight Omicron infections

SARS-CoV-2 Omicron variant uses endosomal entry pathway and grows in upper respiratory tract cells

Emerging SARS-CoV-2 B.1.619 and B.1.620 variants in South Korea

SARS‑CoV‑2 Omicron variant escapes monoclonal antibodies

Lab engineered human A549 lung cell model conducive for investigating SARS-CoV-2 antivirals

SARS-CoV-2 Omicron a product of offensive evolution with compromised antigenicity

Slight pH adjustment may turn a metabolic inhibiting drug into promising COVID-19 treatment

Vaccinated mothers transfer SARS-CoV-2 antibodies to their breastfed infants

NEJM article distills available data into a compendium about rapid diagnostic tests for COVID-19

Scientists discover antibody that inhibits a broad range of sarbecoviruses

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News